Comparative cytotoxicity of oxaliplatin and cisplatin in non-seminomatous germ cell cancer cell lines

Investigational New Drugs

Volumn 15, Issue 2, 1997, Pages 109-114

  Dunn, T A ^a,b   Schmoll, H J ^b   Grunwald V ^a   Bokemeyer, C ^c   Casper, J ^d  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^c UNIVERSITY OF TÜBINGEN   (Germany)

^d UNIVERSITY OF ROSTOCK   (Germany)

Author keywords

Cytotoxic drugs; Drug resistance; Human germ cell cancer; Oxaliplatin

Indexed keywords

CISPLATIN; CYTOTOXIC AGENT; OXALIPLATIN;

ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; CROSS RESISTANCE; DRUG CYTOTOXICITY; GERM CELL TUMOR; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

ADULT; ANTINEOPLASTIC AGENTS; CISPLATIN; DRUG RESISTANCE, NEOPLASM; GERMINOMA; HUMANS; MALE; ORGANOPLATINUM COMPOUNDS; TESTICULAR NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 0030986840     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1005800520747     Document Type: Article

References (41)

1. Bokemeyer C, Berger C, Kynast B, Schmoll HJ, Poliwoda H: Ototoxicity following therapy for testicular cancer. Eur J Cancer 29 A (suppl 6): 1357, 1993
2. Bokemeyer C, Frank B, van Rhee J, Berger C, Schmoll HJ: Peripheral neuropathy following cancer chemotherapy. Long term results in patients with curable neoplasms. Tumordiagn. u. Ther 14:232, 1993
3. Cornelison TL, and Reed E: Nephrotoxicity and hydration management for cisplatin, carboplatin and ormaplatin. Gynecologic Oncology 50:147, 1993
4. Bokemeyer C, Droz JP, Hanauske A, Schmoll HJ: Treatment of relapsed germ cell tumors with vinorelbine: A trial of the phase I/II study group of the association for medical oncology of the German cancer society. Onkologie 16:29-31,1993
5. Harstrick A, Schmoll HJ, Wilke H, Schober C, Stahl M, Wimpner CK, Bokemeyer C, Dolken G, Burk K, Poliwoda H: High-dose epirubicin in refractory or relapsed non-seminomatous testicular cancer: A phase II study. Ann Oncol 1(5):375-376, 1990
6. Bokemeyer C, Schmoll HJ, Natt F, Knoche M, Beyer J, Souchon R: Preliminary results of a phase I/II trial of paclitaxel in patients with relapsed or cisplatin-refractory testicular cancer. J Cancer Res Clin Oncol 120:754-757, 1994
7. Harstrick A, Bokemeyer C, Scharnofkse M, Hapke G, Reile D, Schmoll HJ: Clinical activity of a new platinum analogue, lobaplatin, in cisplatin-sensitive and -resistant human testiuclar, ovarian, gastric carcinoma cell lines. Cancer Chemother Pharmacol 33:43-47, 1993
8. Harstrick A, Casper J, Schmoll HJ: Comparative antitumor activity of cisplatin and two new cisplatin-analogues JM8 and JM9 in human testicular xenografts. Int J Androl 10:139-145, 1987
9. Bajorin DF, Sarosdy MF, Pfister DG, Mazumdar M, Motzer RJ Scher HI, Geller NL, Fair WR, Herr H, Sogani P: Randomised trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: A multi-institutional study. J Clin Oncol 11:598, 1993
10. Bokemeyer C, Schmoll HJ, Harms P, Kohrmann U, Haupt A, Rath U: Randomised comparison of cisplatin (P)versus carboplatin (C)combined with Etoposide (E) and Bleomycin (B) for minimal and moderate disease NSGCT. Ann Oncol 5 (Suppl 8)68, 1994
11. Horwich A, Sleijfer D, Fossa S: A kial of carboplatin-based combination chemotherapy in good prognosis metastatic testicular non-seminoma. Proc of ASCO 13:S709, 1993
12. Siegert W, Beyer J, Strohscheer I, Baurmann H, Oettle H, Zingsern J, Zimmerman R, Bokemeyer C, Schmoll HJ, Huhn D: High-dose treatment with carboplatin, etoposide and ifosfamide followed by autologous stem cell transplantation in relapsed or refractory germ cell tumors - a phase I/II study. J Clin Oncol 12:1223-1231, 1994
13. Kidani Y, Noji M, Tashiro T: Antitumor activity of platinum (II) complexes of 1,2-diaminocyclohexane isomers. Gann 71:637, 1980
14. Brienza S, Bignoud J, Itzhaki M, Krikorian A: Oxaliplatin (L-OHP). Global safety in 682 patients (PTS) Eur J Cancer 31A (Suppl 5):S194, 1995
15. Caussanel JP, Levi F, Brienza S, Misset JL, Itzhaki M, Adam R, Milano G, Hecquet B, Mathe G: Phase I trail of a 5-day continuous venous infusion of oxaliplatin at circadian rhythmmodulated rate compared with constant rate. JNCI 82:1046, 1990
16. Levi F, Misset JL, Brienza S, Adam R, Metzger G, Itzakhi M, Caussanel JP, Kunstlinger F, Lecouturier S, Descorps-Declere A, Jasmin C, Bismuth H, Reinberg A: A chronopharmacologic phase II clinical trial with 5-fluorouracil, folinic acid and oxaliplatin using an ambulatory multichannel programmable pump. Cancer 69(4):893, 1991
17. Levi F, Perpoint B, Garufi C, Focan C, Chollet P, Depres-Brummer P, Zidani R, Brienza S, Itzhaki M, Iacobelli S, Kunstlinger F, Gastiaburu J, Misset JL: Oxaliplatin acitivty against metastatic colorectal cancer. A phase II study of 5-day continuous venous infusion at circadian rhythm modulated rate. Eur J Cancer 29A(9):1280, 1993
18. Llory JF, Soulie P, Cvitkovic E, Misset JL: Feasibility of high-dose platinum delivery with combined carboplatin and oxali-platin. J Natl Cancer Inst 86:8, 1994
19. Fereres M, Llory JF, Soulie P, Garrino C, Gastiaburu J, Brienza S, Bensmaine MA, Misset JL, Cvitkovic E: Prelimiary results of a oxaliplatin (LOHP)-CDDP association based salvage program in platinum (PT) pretreated germ cell tumors (GCT). 8th NCI-EORTC Conference, Amsterdam, 1994
20. Bronson DL, Andrews PW, Vassella RL and Fraley EE: In vitro differentiation of human embryonal carcinoma cells. In Teratocarcinoma Stem Cells; CSH conference on cell 10:597-605, 1983
21. Vogelzang NJ, Bronson DL, Savino D, Vassella R, Fraley EF: A human embryonal-yolk sac carcinoma model system in athymic nude mice. Cancer 55:2584-2593, 1985
22. Casper J, Schmoll H-J, Schnaidt U, Fonatsch C: Cell lines of human germinal cancer. Int J Androl 10:105-113, 1987
23. Skehan P, Storeng R, Scudiero D, Monks A, McMahan J, Vistica D, Warren JT, Bokesch H, Kenney S, Boyd MR: New colorimetric cytotoxicity assay for anticancer drug screening. J Natl Cancer Inst 82:1107-1112, 1990
24. Hill BT, Shellard SA, Fichtinger-Schepman A, Schmoll HJ, Harstrick A: Differential formation and enhanced removal of specific cisplatin-DNA adducts in two cisplatin-selected resistant human testicular teratoma sublines. Anti-Cancer Drugs 5:321-328, 1994
25. Andrews PW, Banting G, Damjanov I, Arnaud D, Avner P: Three monoclonal antibodies defining distinct differentiation antigens associated with different high molecular weight polypeptides on the surface of human embryonal carcinoma cells. Hybridoma 3:347-361, 1984
26. Pera MF, Blasco-Lafita MJ, Cooper S, Mason M, Mills J, Monoghan P: Analysis of cell-differentiation lineage in human teratomas using new monoclonal antibodies to cytostructural antigens of embryonal carcinoma cells. Differentiation 39:139-149, 1988
27. Einhorn LH: Testicular cancer: A model for a curable neoplasm. Cancer Res 41:3275-3280, 1981
28. Pendyala L, and Creaven PJ: In vitro cytotoxicity, protein binding, red blood cell partitioning, and biotrasformation of oxaliplatin. Cancer Research 53:5970, 1993
29. Alvarez M, Ortuzar W, Rixe O, Parker R, Reed E, Fojo T: Cross-Resistance patterns of cell lines selected with platinum suggest differences in the activities and mechanisms of resistance of platinum analoggues. Proceedings of the AACR 35: No. 2616 p439, 1994
30. Ortuzar W, Paull K, Rixe O, and Fojo T: Comparison of the activity of cisplatin (CP) and oxaliplatin (OXALI) alone or in combination in parental and drug resistance sublines. Proceedings of the AACR 35: No. 1974 p332, 1994
31. Fukada M, Ohe Y, Kanzawa F, Oka M, Kohei H and Saijo N: Evalulation of novel platinum complexes, inhibitors of topoisomerase I and II in non-small cell lung cancer (NSCLC) sublines resistant to cisplatin Anticancer Res 15:393, 1995
32. Pera MF, Friedlos F, Mills J, Roberts JJ: Inherent sensitivity of cultured human embryonal carcinoma cells to adducts of cisdiamminedichloroplatinum (II) on DNA. Cancer Res 47:6810-6813,1987
33. Bedford P, Fichtinger-Schepman AMJ, Shellard S, Walker MC, Masters JRW, Hill BT: Differential repair of platinum-DNA adducts in human bladder and testicular tumor continuous cell lines. Cancer Res 48:3019-3024, 1988
34. Kelland LR, Mistry P, Abel G, Friedlos F, Loh SY, Roberts JJ, Harrap KR: Establishment and characterisation of an in vitro model of acquired resistance to cisplatin in a human testicular non-seminomatous germ cell line. Cancer Res 52:1710, 1992
35. Eastman A: The formation, isolation and characterisation of DNA adducts produced by anticancer platinum complexes. Pharac Ther 34:155, 1987
36. Jennerwein MM, Eastman A, Khokhar AR: Characterisation of adducts produced in DNA by isomeric 1,2-diaminocyclohexaneplatinum (II) complexes. Chem Biol Interactions 70:39, 1989
37. Schaller W, Resiner H, Holler E: Kinetic investigation of the DNA platination reaction: evidence for a transient adduct between deoxyribonucleic acid and cisplatinum (II). Biochemistry 26:943, 1987
38. Raymond E, Buquet-Fagot C, Djelloul S, Mester J, Pierre A, Louvet C, Cvitkovic E, Gespach C: Antitumor activity of oxaliplatin in association with 5FU or thymidylate synthase inhibitors. In press
39. Huang H, Zhu L, Reid BR, Drobny GP, Hopkins PB: Solution structure of a cisplatin-induced DNA interstrand cross-link. Science 270:1842, 1995
40. Takahara PM, Rosenzweig AC, Frederick CA, Lippard SJ: Crystal structure of double-stranded DNA containing the major adduct of the anticancer drug cisplatin. Nature 377:649, 1995
41. Pil P, and Lippard SJ: Specific binding of chromosomal protein HMG 1 to DNA damaged by the anticancer drug cisplatin. Science 256:234, 1992